- 1 Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a 2 retrospective cohort study 3 Running Title: Tocilizumab and baricitinib efficacy in COVID-19 4 Yuichi Kojima^a, Sho Nakakubo^{a*}, Keisuke Kamada^{a,b,c}, Yu Yamashita^{a,d}, Nozomu Takei^a, 5 Junichi Nakamura^a, Munehiro Matsumoto^a, Hiroshi Horii^a, Kazuki Sato^a, Hideki Shima^a, 6 Masaru Suzukia, Satoshi Konnoa 7 8 ^{a*} Department of Respiratory Medicine, Faculty of Medicine and Graduate School of 9 Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan. 10 ^b Department of Mycobacterium Reference and Research, The Research Institute of
- 13 ° Department of Epidemiology and Clinical Research, The Research Institute of

Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama Kiyose, Tokyo,

- 14 Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama Kiyose, Tokyo,
- 15 Japan

11

12

Japan.

- 16 d Department of Respiratory Medicine 1, Obihiro Kosei General Hospital, Obihiro,
- 17 Japan.

- 19 Corresponding Author
- 20 Sho Nakakubo
- 21 Department of Respiratory Medicine, Faculty of Medicine and Graduate School of
- 22 Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan.
- 23 E-mail: shonakakubo@pop.med.hokudai.ac.jp
- 24 Tel: +81-11-706-5911

26 Abbreviations 27 BMI: body mass index 28 BRT: baricitinib 29 CI: Confidence interval 30 COVID-19: Coronavirus disease, 2019 31 CRP: C-reactive protein 32 IQR: interquartile rage 33 JAK: Janus kinase inhibitor 34 KL-6: Krebs von den Lungen-6. 35 LDH: lactate dehydrogenase OR: odds ratio 36 37 PCR: Polymerase chain reaction 38 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2 39 TCZ: tocilizumab WBC: White blood cell 40 41

43 Summary 44 Background 45 Although biological agents, tocilizumab and baricitinib, have been shown to improve 46 the outcomes of patients with COVID-19, a comparative evaluation has not been 47 performed. 48 Methods 49 A retrospective, single-center study was conducted using the data of patients with 50 COVID-19 admitted to the Hokkaido University hospital between April 2020 and 51 September 2021, who were treated with tocilizumab or baricitinib. The clinical 52 characteristics of patients who received each drug were compared. Univariate and 53 multivariate logistic regression models were performed against the outcomes of 54 all-cause mortality and the improvement in respiratory status. The development of 55 secondary infection events was analyzed using the Kaplan-Meier analysis and the 56 log-rank test. 57 Results 58 The use of tocilizumab or baricitinib was not associated with all-cause mortality 59 and the improvement in respiratory status within 28 days of drug administration. Age, 60 chronic renal disease, and comorbid respiratory disease were independent prognostic

61 factors for all-cause mortality, while anti-viral drug use and severity of COVID-19 62 at baseline were associated with the improvement in respiratory status. There was 63 no significant difference in the infection-free survival between patients treated 64 with tocilizumab and those with baricitinib. 65 Conclusion 66 There were no differences in efficacy and safety between tocilizumab and baricitinib 67 for the treatment of COVID-19. 68 Keywords: COVID-19, biological agents, tocilizumab, baricitinib, retrospective 69 study. 70

Introduction

71

72 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome 73 coronavirus 2 (SARS-CoV-2), continues to spread worldwide. As various treatment 74 methods have been established and vaccination has progressed, the situation 75 surrounding COVID-19 has entered a new phase. However, the optimal treatment for 76 severe COVID-19 continues to be explored. 77 Steroids were first identified to be effective in the treatment of severe COVID-19 78 and are now considered as the standard treatment (1, 2). Following this, several 79 studies were conducted to determine whether addition of biological agents to the 80 standard treatment could improve prognosis. Tocilizumab (TCZ) is a monoclonal 81 antibody against interleukin-6 receptor-alpha (3). Both REMAP-CAP and RECOVERY 82 trials evaluated the add-on effect of TCZ to the standard of care in hospitalized 83 patients with severe-to-critical COVID-19 and showed that TCZ reduces mortality or 84 prolongs organ support-free days (4, 5). Baricitinib (BRT) is a Janus kinase (JAK) 85 inhibitor with high selectivity for JAK1 and JAK2 molecules of the JAK family (6). 86 It has been observed initially in the ACTT-2 trial that BRT shortens the time to 87 recovery, when used in combination with remdesivir in the treatment of severe COVID-19 88 (7). Further, in the COV-BARRIER trial, treatment with baricitinib, in addition to

89 standard care, was associated with reduced mortality in adults hospitalized with 90 COVID-19 (8). A common finding among these trials was that both TCZ and BRT are 91 particularly effective in reducing mortality in patients with a high demand for 92 oxygen. 93 Based on the evidence, the current guidelines recommend that both TCZ and BRT be 94 administered in combination with steroids to patients with severe COVID-19 requiring 95 high-flow oxygen and non-invasive mechanical ventilation and those with rapidly 96 increasing oxygen needs and systemic inflammation (9, 10). However, to our knowledge, 97 no comparative study exists to verify the superiority of the efficacy of TCZ versus 98 BRT against COVID-19; therefore, the priority among the two is not clearly stated 99 in the current international recommendation (9). 100 Herein, we retrospectively analyzed the medical information of patients with COVID-19 101 admitted to the Hokkaido University Hospital to compare whether the use of TCZ or 102 BRT was associated with mortality, clinical improvement, and incidence of secondary 103 infection.

105 Patients and Methods 106 Patients 107 This single-center, retrospective cohort study was approved by Hokkaido University 108 Hospital Division of Clinical Research Administration (Research No. 020-0107) . The 109 requirement for obtaining informed consent was waived by the relevant ethics 110 committee due to the retrospective nature of the study. This study included patients 111 with COVID-19 who were admitted to the Hokkaido University Hospital between April 112 2020 and September 2021. All patients were confirmed to be positive for SARS-CoV-2 113 by polymerase chain reaction (PCR). Among the patients, those treated with biological 114 agents (TCZ or BRT) for COVID-19 were selected for the present analysis. Cases in 115 which both drugs were administered during the course of treatment were excluded. 116 117 Data collection 118 The clinical data (age, sex, body mass index, history of smoking, history of 119 vaccination, comorbidities, respiratory status and severity, days from the onset of 120 COVID-19, treatment protocol laboratory data, and clinical outcome) were collected 121 from medical records. We defined the severity of COVID-19 as follows: severity level 122 1- hospitalized but not requiring supplemental oxygen; level 2- hospitalized and

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

requiring supplemental oxygen ≤ 4 L per minute (L/min); severity level 3-hospitalized and requiring oxygen therapy ≥ 5 L/min, including receiving nasal high-flow oxygen therapy, non-rebreather, or noninvasive mechanical ventilation; level 4- receiving invasive mechanical ventilation at administration. The reason for setting this severity classification was that in our hospital, the criteria for administering biological agents was when the oxygen administration rate deteriorated to 5 L/min or higher. We set the following clinical endpoints: all-cause mortality, improvement in respiratory status, and development of secondary infection events within 28 days after administration of TCZ or BRT. Improvement in respiratory status was defined as a recovery in severity to level 1 or 2 after the initiation of TCZ or BRT. Secondary infection events included pneumonia, bacteremia, urinary tract infection, and fungal infection requiring antibiotic treatment, Statistical analysis Continuous data are expressed as median and interquartile range (IQR). Categorical data are expressed as absolute number and percentages. Wilcoxon rank sum test or Kruskal-Wallis test was used to compare differences in continuous variables, and

chi-square test or Fisher's exact test was used to evaluate differences between categorical variables. Clinical outcomes including all-cause mortality, improvement in respiratory status, and development of secondary infection events, were analyzed using univariable and multivariate logistic regression models, with odds ratio (OR) and 95 % confidence intervals (CI). Variables with P < 0.1 in the univariate analysis were entered into the multivariate models. Infection-free survival was evaluated by the Kaplan-Meier method with a log-rank test. All P-values were two-tailed, with statistical significance set at P < 0.05. JMP (SAS Institute Inc., Cary, NC, USA) were used for all statistical processing.

150 Results 151 Study population 152 A total of 459 patients were admitted to the Hokkaido University Hospital with the 153 diagnosis of COVID-19 during the study period. Of these, 100 patients received 154 biological agents for treating the symptoms of COVID-19. Sixty-four patients were 155 treated with TCZ (TCZ group) and 34 with BRT (BRT group). Two patients were initially treated with BRT but switched to TCZ, who were excluded from the study (Figure 1). 156 157 158 Baseline characteristics 159 The median age of total patients (N=98) was 60.5 years, and 74.5 % were males (Table 160 1). Compared with the TCZ group (n=64), BRT group (n=34) had lower age (58.5 vs. 65.5 161 years, P=0.03) and lower prevalence of chronic heart disease (5.9% vs. 23.4%, P=0.03). 162 There were no significant differences in sex, smoking history, immunosuppressive drug 163 use, obesity, chronic kidney disease, diabetes mellitus, collagen disease, 164 hypertension, and comorbid respiratory disease. Only one patient in BRT group was 165 fully vaccinated with two doses of the vaccine against SARS-CoV-2. Days from the onset 166 of illness to the administration of biological agents were not significantly 167 different between the two groups (10 vs. 9 days, P=0.50). Analysis of blood samples

168 revealed that, compared to the BRT group, the TCZ group had a significantly lower 169 eosinophil count and hemoglobin (0 vs. 0, P=0.047, 13.8 vs. 14.5, P=0.04, 170 respectively), higher levels of lactate dehydrogenase (LDH), krebs von den Lungen-6 171 (KL-6), and D-dimer (540 vs. 470, P=0.02, 444 vs. 319, P=0.03, 1.5 vs. 1.0, P<0.01, 172 respectively). 173 Most of the patients in both the groups received steroid treatment for COVID-19 (98.4% 174 in TCZ and 97.1 % in BRT group). The TCZ group were administered heparin more 175 frequently and antivirals less frequently than the BRT group (86.0 % vs. 67.7 %, P=0.03, 176 70.3 % vs. 88.2 %, P=0.046, respectively). Only one patient was treated with a 177 combination of the monoclonal antibodies (casirivimab and imdevimab) in the BRT group. 178 The severity of COVID-19 was similar in both groups at the time of initiating treatment 179 with the biological agents, with severity level 3 or higher in 93.2 % of the patients 180 in TCZ group and 85.3 % in BRT group. 181 182 Risk factors for death within 28 days after initiating treatment with biological 183 agents 184 Among the group of patients administered biological agents (N=98), univariate 185 analysis showed that the use of TCZ was significantly associated with increased

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

all-cause mortality. Additionally, increased age, presence of chronic kidney disease, administration of biological agents at less than seven days from onset, and no antiviral drug use were significantly associated with all-cause mortality (Table 2). In multivariate analysis, older age (OR =1.10, 95 % confidence interval (CI) 1.00 -1.21, P=0.02), presence of chronic kidney disease (0R = 43.10, 95 %CI 2.71 - 686.04, P=0.008), and early administration of biological agents from onset (OR = 18.09, 95 %CI 1.70 -192.47, P=0.02) were shown to be independent risk factors for all-cause mortality within 28 days. In contrast, the use of TCZ was not an independent prognostic factor for death (OR = 13.28, 95 %CI 0.45 - 392.92, P=0.13) (Table 2). Factors contributing to improvement in respiratory status In the univariate logistic regression analysis, factors contributing significantly to the improvement of respiratory status were BRT use, young age, absence of chronic heart disease, chronic kidney disease or hypertension, more than seven days from onset to drug administration, and use of any anti-viral drug (Table 3). However, in multivariate analysis, BRT use was not a contributing factor (OR = 1.75, 95 %CI 0.35 -8.67, P=0.50), while the use of the anti-viral drug was an independent contributing factor (OR =6.5, 95 %CI 1.13 - 37.56, P=0.04). Early administration of biological

204 agents was the risk factor that reduced the likelihood of improving the respiratory status (OR = 0.82, 95 %CI 0.02 - 0.40, P=0.002). 205 206 207 Development of secondary infection 208 The rates of acquiring any secondary infection in patients within 28 days after 209 initiation of treatment with TCZ and BRT were 15.6 and 14.7%, respectively. Univariate 210 analysis did not identify any factors associated with the development of secondary 211 infection after initiation of treatment with biological agents (Supplementary table). 212 There was also no significant difference in infection-free survival (P=0.95) (Figure

213

2).

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

Discussion In this retrospective study, we compared the clinical characteristics between two groups of patients treated with TCZ and BRT for COVID-19. Multivariate analysis revealed that both the biological agents did not increase all-cause mortality within 28 days of treatment initiation. Age, underlying diseases, and early administration of biological agents were independent risk factors for all-cause mortality. None of the two biological agents significantly contributed to improving the respiratory status within 28 days. Use of anti-viral drugs and late administration of biological agents significantly contributed to improvement in respiratory status. No significant difference was observed in the development of secondary infection within 28 days after TCZ or BRT administration. The results of this study showed that most of the patients who were treated with TCZ or BRT were also receiving steroid therapy. In addition, the severity of COVID-19 at the time of initiating treatment with biological agents was not significantly different between the two groups. In our hospital, patients with COVID-19 who required oxygen are usually treated with steroids, and biological agents are additionally

administered to patients with increased oxygen demand, based on the guideline

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

treatment plan (9, 10). Although the present study was retrospective, the strength of the study was that the baseline treatment and respiratory status of both groups are well matched. According to the results of univariate analysis, TCZ seemed to increase the risk of 28-day mortality, while not improving the respiratory status. However, it was not identified as a significant risk factor in multivariate analysis. The reason for this could be due to the existence of multiple confounding factors for the use of TCZ. Comparison of clinical characteristics between the TCZ and BRT groups revealed an older median age and a higher proportion of patients with chronic diseases in the TCZ group, than in the BRT groups. Moreover, blood test results showed higher levels of LDH and D-dimer in the TCZ group than that in the BRT group. Advanced age and presence of underlying diseases are considered poor prognostic factors for COVID-19 (11, 12). Higher levels of LDH and D-dimer are associated with increased mortality in COVID-19 and are known to be predictors of severe disease (13). Although we did not find a significant difference in the severity of COVID-19 based on respiratory status, TCZ group might have potentially been at a higher risk for critical course. TCZ was shown to be effective relatively earlier than BRT in the COVID-19 pandemic and was used earlier in clinical practice. In contrast, BRT became widely used in

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

Japan after approval for the treatment of COVID-19. In addition, backgrounds of the patients admitted to our hospital differed depending on the timing of spread of COVID-19. These circumstances might contribute to the bias in the clinical characteristics of the two groups. Biological drugs are a risk factor for serious infection in rheumatoid arthritis (14). Although the COVID-19 trials showed no difference in the incidence of infections in either TCZ or BRT groups, compared to that in the placebo (4, 8), one retrospective study showed that concomitant use of TCZ and methylprednisolone is a risk factor for bacteremia (15). Besides, whether there is a difference in the risk of developing infections between TCZ and BRT has not been evaluated earlier. In our study, we found no difference in the incidence of secondary infection between TCZ group and BRT group. In addition, no risk factors were identified in the univariate analysis, which could be associated with the occurrence of secondary infection. Although we have not been able to verify whether the complications of infections had an impact on patient prognosis, neither biological drug seems to pose a significant risk of infection. Given the fact that treatment with any of the two biological agents did not result

in significantly different outcomes for patients, either TCZ or BRT can be selected

in terms of efficacy and safety. BRT is an oral drug that can be administered even if the intravenous route is difficult to secure, and it is easy to discontinue. Tocilizumab is an intravenous or subcutaneous drug that can be used by patients who have difficulty with oral intake and in those with severe renal dysfunction. The choice should be based on the characteristics of each drug in each individual patient. Our study confirmed that the improvement of patients' respiratory status in COVID-19 was similar with both biological agents. In contrast, we found that the use of anti-viral drugs was significantly associated with improvement in respiratory status within 28 days. According to the clinical trial, remdesivir has been shown to shorten the time to recovery in patients hospitalized with COVID-19 and with evidence of pneumonia (16). In contrast, several studies have failed to show clear efficacy (17-19); the efficacy of remdesivir as a single agent or adjunctive drug for standard care may be limited. Based on the results of our study, remdesivir may be an important drug that should essentially be administered to patients receiving biologic agents and steroids. This finding suggests the additive effect of remdesivir, which requires further investigation.

Ü

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

It is worth discussion that shorter time from the onset of illness to the administration of the biological drugs was an independent factor for poor prognosis. For both TCZ and BRT, earlier administration of drugs in the trials is associated with a greater reduction in the risk of death (5, 8). The reason of this apparently paradoxical observation was probably that the short time between the onset of symptoms and the administration of biological agents may reflect the rapid deterioration in respiratory status. In our hospital, biologic drugs are mostly administered to patients with increased oxygen demand and increased severity of illness. Worsening of respiratory status early in the course of the disease may be a prognostic factor that cancels out the benefit of early administration of biological drugs. The prognosis of patients who deteriorate rapidly after the onset of illness should be evaluated in future studies. This study has several limitations. First, since the study was retrospective, prospective validation is needed to show the comparative efficacy of TCZ and BRT. Second, variant strains of SARS-CoV-2 and changes in healthcare availability that may affect patient outcomes were not validated in this study due to lack of data.

Lastly, the efficacy of using the biological agents as a standalone treatment for COVID-19 was not verified in this study. However, the efficacy of TCZ and BRT has already been proven in previous studies. Our study was conducted to suggest a more favorable treatment based on these evidence-based practices of using TCZ and BRT.

In conclusion, the use of TCZ versus BRT had no different impact on all-cause mortality, improvement in respiratory status, and the development of secondary infection in patients diagnosed with COVID-19. In light of our findings, both biological agents are expected to be equally safe and clinically effective, although future prospective studies are needed.

315 Acknowledgements 316 Not applicable. 317 318 Conflict of Interest 319 The authors state that they have no conflict of interest (COI). 320 321 Funding 322 This research did not receive any specific grant from funding agencies in the public, 323 commercial, or not-for-profit sectors. 324 325 Ethical approval 326 The research protocol was approved by the Ethics Committee of the Hokkaido University 327 Hospital (Research No. 020-0107). The study was based on existing samples collected 328 in the course of routine practice and no additional risks are posed to patients. Therefore, the individual's informed consent was waived by the above ethics 329 330 committee. Informed consent for study participation was officially announced on the 331 website. All patient data were anonymized prior. 332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

diseases.

Best

Pract

Contributions YK and SN contributed to the study concept and design and interpretation, statistical analysis, and drafting of the manuscript. KK, YY, NT, JN, MM, HH, KS and HS contributed to the acquisition and interpretation of data. NT contributed to statistical analysis. YK, SN, and MM contributed to data acquisition. MS and SK contributed to the study concept and design, acquisition and interpretation of data, and finalization of the manuscript. All authors read and approved the final manuscript. References Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. DOI: 10.1056/NEJMoa2021436 2. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. Jama. 2020;324(13):1307-16. DOI: 10.1001/jama.2020.17021 3. Kaly L, Rosner I. Tocilizumab - a novel therapy for non-organ-specific autoimmune

Clin

Res

Rheumatol.

2012;26(1):157-65.

DOI:

- 351 10.1016/j. berh. 2012.01.001
- 352 4. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al.
- 353 Interleukin-6 Receptor Antagonists in Critically II1 Patients with Covid-19. N Engl J
- 354 Med. 2021;384(16):1491-502. DOI: 10.1056/NEJMoa2100433
- 355 5. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a
- 356 randomised, controlled, open-label, platform trial. Lancet. 2021;397 (10285):1637-45.
- 357 DOI: 10.1016/s0140-6736(21)00676-0
- 358 6. Emery P, Durez P, Hueber AJ, de la Torre I, Larsson E, Holzkämper T, et al.
- 359 Baricitinib inhibits structural joint damage progression in patients with rheumatoid
- 360 arthritis—a comprehensive review. Arthritis Res Ther. 2021;23(1):3. DOI:
- 361 10.1186/s13075-020-02379-6
- 362 7. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al.
- 363 Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med.
- 364 2021;384(9):795-807. DOI: 10.1056/NEJMoa2031994
- 365 8. Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy
- 366 and safety of baricitinib for the treatment of hospitalised adults with COVID-19
- 367 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3
- 368 trial. Lancet Respir Med. 2021. DOI: 10.1016/s2213-2600(21)00331-3

- 369 9. Infectious Diseases Society of America Guidelines on the Treatment and
- 370 Management of Patients with COVID-19. Infectious Diseases Society of America 2021;
- 371 Version 5.6.0. Available at
- 372 https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-manage
- 373 ment/. Accessed 1^{st} , Dec. 2021.
- 374 10. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19)
- 375 Treatment Guidelines. National Institutes of Health. Available at
- 376 https://www.covid19treatmentguidelines.nih.gov/. Accessed 1st, Dec. 2021.
- 377 11. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors
- for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428-55.
- 379 DOI: 10.1111/a11.14657
- 380 12. Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical
- 381 epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19
- 382 REGISTRY JAPAN. Clin Infect Dis. 2020. DOI: 10.1093/cid/ciaa1470
- 383 13. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors
- 384 of COVID-19 severity: A literature review. Rev Med Virol. 2021;31(1):1-10. DOI:
- 385 10.1002/rmv.2146
- 386 14. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al.

- 387 Risk of serious infection in biological treatment of patients with rheumatoid arthritis:
- 388 a systematic review and meta-analysis. Lancet. 2015;386(9990):258-65. DOI:
- 389 10. 1016/s0140-6736 (14)61704-9
- 390 15. Badr M, De Oliveira B, Abdallah K, Nadeem A, Varghese Y, Munde D, et al. Effects
- 391 of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with
- 392 Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study. J Clin Med.
- 393 2021;10(4). DOI: 10.3390/jcm10040760
- 394 16. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir
- 395 for the Treatment of Covid-19 Final Report. N Engl J Med. 2020;383(19):1813-26. DOI:
- 396 10. 1056/NE JMoa 2007764
- 397 17. Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi
- 398 D, et al. Remdesivir plus standard of care versus standard of care alone for the
- 399 treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3,
- 400 randomised, controlled, open-label trial. Lancet Infect Dis. 2021. DOI
- 401 10. 1016/s1473-3099 (21) 00485-0
- 402 18. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim
- 403 Q, et al. Repurposed Antiviral Drugs for Covid-19 Interim WHO Solidarity Trial Results.
- 404 N Engl J Med. 2021;384(6):497-511. DOI: 10.1056/NEJMoa2023184

405 19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with 406 severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. 407 Lancet. 2020;395(10236):1569-78. DOI: 10.1016/s0140-6736(20)31022-9 408

Table 1. Comparison of baseline characteristics between tocilizumab and baricitinib groups.

	Total (N=98)	Tocilizumab (n=64)	Baricitinib (n=34)	<i>P</i> -value
Characteristics				
Age (year)	60. 5 (54. 0, 70. 3)	65. 5 (54. 3, 72. 8)	58. 5 (53. 8, 64. 3)	0. 03
Sex(male)	73 (74.5)	46 (71. 9)	27 (79.4)	0. 42
Current smoker	16 (16.3)	9 (16.5)	7 (20.6)	0. 41
$BMI \ge 30 \text{ (kg/m}^2) *$	25 (27.2)	18 (30.0)	7 (20.6)	0.40
Chronic heart disease	17 (17.4)	15 (23. 4)	2 (5. 9)	0. 03
Chronic kidney disease	6 (6.1)	4 (6.3)	2 (5. 9)	0. 94
Diabetes mellitus	36 (36.7)	23 (35. 9)	13 (38. 2)	0.82
Any collagen disease	3 (3.1)	3 (4.7)	0 (0)	0. 20
Hypertension	46 (46.9)	34 (53. 1)	12 (35. 3)	0.09
Any respiratory disease	8 (8.1)	6 (9.4)	2 (5. 9)	0. 55
Immunosuppressive	3 (3.1)	2(3.1)	1 (2. 9)	0. 96
drug regular use				
Twice vaccinated	1 (1.0)	0 (0)	1 (1.0)	0. 14
Time from symptom onset	9 (7, 12)	10 (7, 13)	9 (7, 11)	0. 50
to administration				
Time from onset to	29 (29.6)	19 (29.7)	10 (29.4)	0. 98
administration≦7 days Treatment				
Steroid	96 (98.0)	63 (98.4)	33 (97. 1)	0. 65
Heparin	78 (79.6)	55 (86.0)	23 (67.7)	0. 03
Any anti-viral drug	75 (76.5)	45 (70.3)	30 (88. 2)	0.046
Antibody cocktail	1 (1.0)	0 (0)	1 (1.0)	0. 14
therapy				
Blood test at				
administration				
White blood cell (/ μ L)	7900 (5550,	8000 (5400, 11075)	7700 (5600,	0.64

	10825)		10525)	
Neutrophils (/μL) **	6991 (4465, 9755)	7173 (4716, 10027)	6780 (4418, 9280)	0. 53
Lymphocytes (/μL) **	611 (476, 908)	648 (440, 911)	608 (528, 852)	0. 65
Eosinophil (/μL) **	0 (0, 0)	0 (0, 0)	0 (0, 8.3)	0. 047
Hemoglobin (g/dL)	14. 2 (12. 9, 15. 0)	13.8 (12.8, 15.0)	14. 5 (13. 9, 15. 6)	0.04
Platelet ($ imes 10^4/\mu$ L)	19.0 (13.4, 25.9)	18.5 (12.7, 25.8)	20.7 (14.8, 26.4)	0. 51
LDH (U/L)	512. 5 (419. 8,	540 (438. 8, 716. 0)	470. 5 (386. 5,	0. 02
	647.5)		603.5)	
CRP (mg/mL)	7. 1 (3. 6, 11. 2)	7.8 (3.9, 12.1)	5.8 (3.1, 9.4)	0. 12
KL-6 (U/mL) ***	402 (289. 5,	444 (337, 705)	319 (240. 3,	0. 03
	617.5)		481.5)	
Procalcitonin (ng/mL) ****	0.08 (0.05, 0.15)	0.08 (0.06, 0.12)	0.08 (0.05, 0.18)	0. 97
Ferritin (ng/mL) ****	1125. 5 (693. 8,	1242. 5 (745. 3,	1080 (631. 8,	0. 44
	1924. 5)	1966. 3)	1901)	
D-dimer (μg/mL)*****	1.4 (1.0, 2.5)	1.5 (1.3, 3.1)	1.0 (0.8, 1.4)	<0.001
Severity				
1	1 (1)	1 (1.6)	0 (0)	
2	9 (9.2)	4 (6.3)	5 (14.7)	
3	76 (77.6)	49 (76.6)	27 (79.4)	
4	12 (12. 2)	10 (15. 6)	2 (5. 9)	0. 26

- 11 *N=92 **N=94 ***N=69 ****N=60 ****N=70 *****N=95
- 12 Data are shown as median (interquartile range) or number (%).
- 13 We defined COVID-19 disease severity at administration as follows: severity level 1, hospitalized but
- 14 not requiring supplemental oxygen; level 2, hospitalized and requiring supplemental oxygen ≤ 4 L per
- minute (L/min); severity level 3, hospitalized and requiring oxygen therapy ≥ 5 L/min or receiving nasal

- 16 high-flow oxygen therapy, non-rebreather, or noninvasive mechanical ventilation; level 4, receiving
- 17 invasive mechanical ventilation at administration.

19

18 BMI, body mass index; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase.

Table 2. Predicting factors for death within 28 days of administration in patients treated with

tocilizumab or baricitinib assessed using logistic regression analysis.

20

	Univariate		Multivariate	
	OR (95%CI)	<i>P</i> -value	OR (95%CI)	<i>P</i> -value
Characteristic				
Tocilizumab use	8. 41 (1. 05-67. 37)	0.045	13. 28 (0. 45-392. 92)	0. 13
Age (year)	1. 10 (1. 03-1. 18)	0.004	1. 10 (1. 00-1. 21)	0.04
Sex(male)	0.38 (0.12-1.26)	0. 12		
Current smoker	0.35 (0.04-2.92)	0. 33		
$BMI \ge 30 \ (kg/m^2)$	0. 94 (0. 27-3. 30)	0. 93		
Chronic heart disease	2. 18 (0. 59-8. 03)	0.24		
Chronic kidney disease	16. 40 (2. 66-101. 21)	0.003	43. 10 (2. 71-686. 04)	0.008
Diabetes mellitus	1. 35 (0. 43-4. 26)	0.61		
Any collagen disease	3. 15 (0. 27-37. 31)	0.36		
Hypertension	2. 29 (0. 70-7. 40)	0. 17		
Any respiratory	4. 31 (0. 90-20. 59)	0.07	1.85 (0.22-15.76)	0. 57
disease				
Immunosuppressive	3. 15 (0. 27-37. 31)	0.36		
drug regular use				
Time from onset to	5. 76 (1. 73-19. 18)	0.004	18.09 (1.70-192.47)	0.02
administration≦7 days				
Treatment				
Heparin	1. 64 (0. 34-7. 98)	0. 54		
Any anti-viral drug	0. 34 (0. 10–1. 11)	0.07	0. 16 (0. 01–1. 96)	0. 15
111, 411, 111, 41, 41	0.01 (0.10 1.11)		0.10 (0.01 1.00)	V, 15
Blood test at				
administration				
Lymphocytes	0.36 (0.01-13.81)	0.58		
$(imes 10^3/\mu$ L)				
Platelet ($ imes 10^5/\mu$ L)	0.66 (0.35-1.24)	0.20		
LDH $(\times 10^2 \text{U/L})$	1. 18 (0. 88-1. 59)	0. 27		
CRP (mg/mL)	1.02 (0.92-1.13)	0.68		
KL-6 ($\times 10^2$ U/mL)	1.06 (0.87-1.30)	0. 57		
Procalcitonin (ng/mL)	1. 36 (0. 18-9. 97)	0.76		
Ferritin ($\times 10^3 \text{ng/mL}$)	0.37 (0.10-1.47)	0. 16		

D-dimer (
$$\mu$$
 g/mL) 0.10 (0.96-1.03) 0.82

Severity

29

1 or 2	(reference)	(reference	
)	
3	1. 52 (0. 18-13. 24)	0.70	
4	1.80 (0.14-23.37)	0.65	


- 22 We defined COVID-19 disease severity at administration as follows: severity level 1, hospitalized but
- 23 not requiring supplemental oxygen; level 2, hospitalized and requiring supplemental oxygen ≤ 4 L per
- 24 minute (L/min); severity level 3, hospitalized and requiring oxygen therapy ≥ 5 L/min or receiving nasal
- 25 high-flow oxygen therapy, non-rebreather, or noninvasive mechanical ventilation; level 4, receiving
- 26 invasive mechanical ventilation at administration.
- 27 BMI, body mass index; CI, Confidence interval; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6;
- 28 LDH, lactate dehydrogenase; OR, odds ratio.

Table 3. Predicting factors for improvement in respiratory status within 28 days of administration in patients treated with tocilizumab or baricitinib assessed using logistic regression analysis.

	Univariate		Multivariate	
	OR (95%CI)	<i>P</i> -value	OR (95%CI)	<i>P</i> -value
Characteristics				
Baricitinib use	3. 66 (1. 14-11. 76)	0. 03	1.75 (0.35-8.67)	0. 50
Age (year)	0. 94 (0. 89-0. 98)	0.004	0.94 (0.88-1.01)	0.07
Sex(male)	1. 55 (0. 57-4. 22)	0.39		
Current smoker	6. 21 (0. 78-49. 65)	0.09	4. 14 (0. 28-60. 37)	0.29
$BMI \ge 30 \ (kg/m^2)$	1. 46 (0. 47-4. 49)	0. 50		
Chronic heart disease	0. 27 (0. 09-0. 80)	0.03	0.40 (0.09-1.89)	0.25
Chronic kidney disease	0. 15 (0. 03-0. 86)	0.03	0.12 (0.01-1.80)	0. 13
Diabetes mellitus	1. 04 (0. 40-2. 68)	0. 93		
Any collagen disease	0. 68 (0. 07-9. 12)	0.75		
Hypertension	0. 39 (0. 15-1. 01)	0.047	0.84 (0.20-3.59)	0.82
Any respiratory disease	0. 54 (0. 12-2. 44)	0.42		
Immunosuppressive	0.67 (0.05-7.79)	0.75		
drug regular use				
Time from onset to	0. 26 (0. 10-0. 68)	0.006	0.82 (0.02-0.40)	0.002
administration≦7 days				
Treatment				
Heparin	0. 97 (0. 31-3. 00)	0. 95		
Any anti-viral drug	3. 99 (1. 46-10. 89)	0.007	6. 5 (1. 13-37. 56)	0.04
Blood test at				
administration				
Lymphocytes ($ imes 10^3/\mu$ L)	1. 07 (0. 92-1. 24)	0.37		
Platelet ($ imes 10^5/\mu$ L)	1. 37 (0. 84-2. 24)	0.20		
LDH $(\times 10^2 \text{U/L})$	0.85 (0.66-1.09)	0. 19		
CRP (mg/mL)	1. 01 (0. 92-1. 09)	0. 91		
KL-6 ($\times 10^2$ U/mL)	0. 91 (0. 78-1. 06)	0. 25		
Procalcitonin (ng/mL)	1. 08 (0. 13-12. 74)	0.83		
Ferritin (ng/mL)	1. 15 (0. 65-2. 03)	0.64		
D-dimer (μ g/mL)	0. 98 (0. 95-1. 00)	0.09	0. 98 (0. 96-1. 01)	0. 25

Severity				
1 or 2	(reference)	(reference)	(reference)	(reference)
3	0.36 (0.04-3.02)	0. 35		
4	0. 11 (0. 01-1. 17)	0.07	0.04 (0.002-1.01)	0.05
We defined COVID-19 disea	ase severity at administra	tion as follows: s	severity level 1, hos	spitalized but
not requiring supplemental oxygen; level 2, hospitalized and requiring supplemental oxygen ≤ 4 L per				
minute (L/min); severity level 3, hospitalized and requiring oxygen therapy ≥ 5 L/min or receiving nasal				
high-flow oxygen therapy, non-rebreather, or noninvasive mechanical ventilation; level 4, receiving				
invasive mechanical ventilation at administration.				
BMI, body mass index; CI,	Confidence interval; CRP	, C-reactive prote	ein; KL-6, Krebs von	den Lungen-6;

LDH, lactate dehydrogenase; OR, odds ratio.



44

46

43 Figure 1. Flow chart of patients with COVID-19 with the tocilizumab and baricitinib groups.

Figure 2. Kaplan-Meier estimates of infection-free survival between tocilizumab and baricitinib.

